Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Biointron’s RushData platform combines AI-driven antibody discovery, high-throughput laboratory testing and rapid CHO cell expression to help researchers evaluate promising biologic candidates faster. Representative image.
Pharma & Biotech

AI can design thousands of antibodies, but can Biointron’s RushData test them fast enough?

Biointron’s RushData combines one-day CHO expression, binding assays and developability data to accelerate AI antibody discovery.

Read More
Otsuka’s FDA approval of SIMTRIYO, or centanafadine, introduces a first-in-class ADHD treatment for adults and children aged six and older, although DEA scheduling, safety monitoring and payer access will shape its commercial adoption. Representative image.
Pharma & Biotech

Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care

Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.

Read More
Representative image: A pediatric neurology consultation and brain MRI review illustrate leriglitazone’s positive European recommendation for boys with early-stage cerebral adrenoleukodystrophy.
Pharma & Biotech

Minoryx Therapeutics secures exceptional-circumstances CHMP recommendation for leriglitazone

Leriglitazone wins a positive European opinion for boys with early cerebral adrenoleukodystrophy after a narrower pediatric application.

Read More
Merck is preparing a global access network for alimatravir as the investigational once-monthly oral HIV PrEP candidate advances through Phase 3 trials, with efficacy, affordability and manufacturing readiness set to determine its future public health impact. Representative image.
Pharma & Biotech

Merck is licensing alimatravir before Phase 3 ends. Can a monthly HIV pill beat the access clock?

Merck’s alimatravir access plan covers 129 countries, but Phase 3 efficacy, pricing and regulatory execution will decide its HIV PrEP impact.

Read More
A patient receives infusion-based breast cancer care as clinicians review treatment imaging, reflecting the CHMP recommendation for Gilead Sciences’ Trodelvy plus Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer. Representative image.
Pharma & Biotech

Gilead’s Trodelvy cleared a key EU hurdle, but can it really replace chemotherapy in first-line TNBC?

CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic TNBC, moving Gilead closer to an expanded EU label.

Read More
A hospital researcher examines bacterial cultures as Apollo Hospitals and Precisio Biotix advance lysin-based antimicrobial research targeting drug-resistant infections and India’s growing antimicrobial resistance challenge. Representative image.
Pharma & Biotech

What the Apollo Hospitals and Precisio Biotix lysin partnership means for India’s AMR crisis

Apollo Hospitals and Precisio Biotix plan lysin research and expanded access in India as antimicrobial resistance pressure intensifies.

Read More
Representative image: An adult receives a rapid at-home autoinjector treatment as MannKind Corporation’s $MNKD Furoscix ReadyFlow wins FDA approval for edema linked to heart failure and chronic kidney disease.
Pharma & Biotech

MannKind Corporation wins FDA approval for 10-second Furoscix ReadyFlow furosemide autoinjector

FDA approves MannKind Corporation’s Furoscix ReadyFlow for heart failure and CKD edema. See how the 10-second autoinjector may change care.

Read More
Par Health’s launch of the first generic Janumet XR introduces new U.S. competition for sitagliptin and extended-release metformin tablets used in type 2 diabetes care. Representative image.
Pharma & Biotech

Why Par Health’s first generic Janumet XR launch could trigger a rapid U.S. pricing reset

Par Health launches the first U.S. generic Janumet XR, opening a $270 million diabetes market to new pricing and formulary competition.

Read More
NADclinic and Geneva College of Longevity Science are linking clinician education with longevity and performance medicine as the sector pushes for stronger evidence, regulatory awareness and responsible clinical practice. Representative image.
Pharma & Biotech

Can NADclinic and GCLS turn longevity medicine’s training gap into a clinical standard?

NADclinic and GCLS are linking postgraduate education with longevity practice as evidence, regulation and clinical governance face scrutiny.

Read More
Harbour BioMed’s antibody discovery platforms and global biopharma partnerships are supporting revenue growth and a seventh consecutive profitable half-year, although the company’s full interim results will determine the durability of its earnings momentum. Representative image.
Pharma & Biotech

Harbour BioMed’s revenue is climbing, but one profit number complicates the growth story

Harbour BioMed expects up to $67 million interim profit as antibody deals lift revenue, but margin trends will shape the next investor debate.

Read More